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1. Age (months)
2. Sex
3. Body weight at surgery (kilograms)
4. Body surface area (square meters)
5. Diagnosis
6. Isomerism
7. Hypoplastic left heart syndrome
8. Previous Norwood procedure
9. Timing of surgery
10. Ventricular morphology (left, right, indeterminate)
11. Atrioventricular valve morphology
12. Prerepair atrioventricular valve regurgitation grade
13. Atrioventricular valve annulus size (millimeters)
14. Indexed atrioventricular valve annulus size (millime-
ters per square meter)
15. Affected leaflet: anterior, posterior, septal, mural or
lateral, other
16. Regurgitation mechanism: annular dilatation (yes/no)
17. Regurgitation mechanism: cleft (yes/no)
18. Regurgitation mechanism: prolapse (yes/no)
19. Regurgitation mechanism: chordal elongation (yes/no)
20. Regurgitation mechanism: chordal deficiency (yes/no)
21. Regurgitation mechanism: leaflet restriction (yes/no)
22. Regurgitation mechanism: leaflet thickening (yes/no)
23. Regurgitation mechanism: dysplasia (yes/no)
24. Regurgitation mechanism: papillary muscle abnormal-
ities (yes/no)
25. Regurgitation mechanism: endocardial fibroelastosis
(yes/no)
26. Pre repair ventricular function (grade 0–3)
27. Pre repair ventricular dilatation (grade 0–3)
28. Primary mechanism of atrioventricular valve regurgita-
tion
29. Secondary mechanism of atrioventricular valve regur-
gitation
30. Ventricular dimension (millimeters)
31. Indexed ventricular dimension (millimeters per square
meter)
32. Surgical technique: annuloplasty
33. Surgical technique: commissuroplasty
34. Surgical technique: valvuloplasty
35. Surgical technique: chordal repair
36. Surgical technique: cleft closure334 The Journal of Thoracic and Cardiovascular Surg37. Surgical technique: edge-to-edge repair
38. Papillary muscle repair
39. Aortic crossclamp time (minutes)
40. Cardiopulmonary bypass time (minutes)
41. Deep hypothermic circulatory arrest (yes/no)
42. Deep hypothermic circulatory arrest time (minutes)
43. Intraoperative transesophageal echocardiogram: resid-
ual atrioventricular valve regurgitation (grade 0–3)
44. Intraoperative transesophageal echocardiogram: residual
atrioventricular valve stenosis (grade 0–3)
45. Intraoperative transesophageal echocardiogram: ven-
tricular function (grade 0–3)Discussion
Dr Jennifer C. Hirsch (Ann Arbor, Mich). Congratulations on
a nicely presented article. I am pleased to have the opportunity to
discuss this excellent presentation by Dr Honjo and colleagues at
The Hospital for Sick Children in Toronto.
As mentioned, the progression of AV regurgitation in a single-
ventricle population poses a significant challenge regarding
surgical options, timing of intervention, and long-term prognosis.
With limited donor availability, every attempt to remediate ven-
tricular and atrioventricular function in the native heart is the ideal
objective.
Dr Honjo, you have presented excellent outcomes for patients in
whom successful repair has been accomplished. The incorporation
of the case–control study provides a valuable attempt to bench-
mark the outcomes against those of the overall single-ventricle
population. Your presentation, as well as the manuscript that you
submitted earlier, is thought provoking regarding our ownmanage-
ment strategies.
First, it appears that your center has been fairly aggressive at in-
tervening for even mild to moderate AV regurgitation at an early
age. We have found significant improvement in the degree of AV
regurgitation with the volume unloading effects of the second-
stage cavopulmonary connection, and therefore we have not
been intervening for moderate or less AV regurgitation at that
stage. Looking at the relatively small percentage of patients within
your study who did have AV repair, how is the decision made to
intervene for some of the patients with only mild to moderate re-
gurgitation and not others? And do you know the natural history
of those patients who do not have intervention, perhaps through
your case–control study?
Dr Honjo. That’s a very good point. Our strategy is to take
a look at the AVat stage II palliation if patient has a mild to mod-
erate regurgitation, regardless of the mechanism of regurgitation.
Our study shows that the vast majority of patients actually have
anatomic abnormality, rather than just functional regurgitation.
So it’s worth to taking a look at the AV. If there is anatomic issue
detected, we can adequately fix it.
We didn’t have enough patients with mild to moderate or mod-
erate regurgitation who didn’t undergo an AV repair to conduct
a good matching study to compare or look at the natural history
of unrepaired patient outcome. There is a study from Philadelphia
showing that patients with mild to moderate regurgitation, or even
moderate regurgitation, who did not have repair at the stage IIery c August 2011
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Doperation did reasonably well after the stage II palliation. The
study also suggested, however, that some of these patients required
the valve repair at the Fontan operation. We believe that the pres-
ervation of ventricle geometry and function is crucial, so our con-
sistent strategy is to intervene in cases of borderline mild to
moderate regurgitation at the stage II palliation.
Dr Hirsch. Second, given the high prevalence of single right
ventricle and primary tricuspid valve morphologies, do you be-
lieve that the development of significant AV regurgitation is a result
of the morphologically right ventricle being incapable of function-
ing as well under systemic pressures? If so, should these patients
be managed differently from a medical standpoint, such as more
aggressive afterload reduction to mitigate this risk and stabilize
the annulus?
Dr Honjo. I think that’s a good point. In our patient group, more
than 80%of the patients havemorphologically right ventriclewith ei-
ther anatomic tricuspid valve or commonAV. If they start to have AV
regurgitation or progressive ventricular dilatation, they need aggres-
sivemedical therapy to reduce afterload.We believe that to intervene
for those patients at stage II is part of an overall strategy that willmin-
imize irreversible changes in ventricular function and geometry.
Dr Hirsch. Given the variable approaches to annuloplasty and
partial annuloplasty in this patient population that have been re-
ported, do you use a standard technique for your annuloplasty?
If so, what is that technique?
Dr Honjo.We used very standard techniques. We only use the
ring annuloplasty or circumferential annuloplasty when the annu-
lus is at or near adult size. More than 95% of the patients actually
have localized annuloplasty where the leak originates. We also
combine either anatomic functional commissuroplasty at the loca-
tion of the regurgitation. Some patients underwent edge-to-edge
type repairs, especially the patient with common AV.
DrHirsch.Do you think that with the coming availability of the
bioabsorbable ring that perhaps you’ll use that more frequently in
this patient population to further stabilize the annulus?
Dr Honjo. You mean the artificial ring?
Dr Hirsch. Bioabsorbable.
Dr Honjo. I’m not sure.
Dr Hirsch. It’s not yet commercially available. I’m thinking in
the future of new technologies that may benefit these patients.
Dr Honjo. Right. That might be a good idea.
Dr Hirsch. Finally, given the increased risk of failure in your
patients with poor ventricular function and significant annular
dilatation, do you believe that early listing for transplant may be
appropriate for this patient population?The Journal of Thoracic and CaDr Honjo. That’s a good point. I think that we have to consider
transplant early when we have a patient who has reduced ventric-
ular function after AV repair. Those are the patients who are at
really high risk of death or transplant anyway. The issue is that
we cannot predict who is going to have postrepair severe ventric-
ular dysfunction according to the preoperative values in our study.
That’s one thing we have to sort out in a future study.
Dr Hirsch. Again, congratulations on an outstanding presenta-
tion and exemplary results in a very difficult patient population.
Dr Honjo. Thank you very much.
Dr Peter B. Manning (Cincinnati, Ohio).You said that most of
your valves were anatomically abnormal and that most of your pa-
tients had hypoplastic left heart syndrome, and I don’t think we
usually think of patients with hypoplastic left heart syndrome as
having anatomically abnormal tricuspid valves. Are you basing
the characterization of abnormal on the fact that you had a high
percentage of annular dilatation and prolapse according to echo-
cardiography? Annular dilatation with reference to what normal
value? I’m guessing there probably aren’t normal values for sin-
gle-ventricle annular dimensions. With your case–control study,
you might have a comparison group to justify that.
I also worry that prolapse may also be a function more of ven-
tricular dysfunction than of actual anatomic findings. So were the
surgical intraoperative findings consistent with what you’re char-
acterizing as echocardiographic anatomic abnormalities? That is
my first question.
DrHonjo. That’s a very good point.We actually are performing
an ongoing study correlating the surgical and echocardiographic
findings in this study. We do, however, have a fair correlation be-
tween the evaluation of the echocardiograms that were done in this
study and actual surgical findings. The pathologic study also
showed that more than a third of the patients with hypoplastic
left heart syndrome actually had anatomic abnormality, mainly
dysplasia, so it’s not surprising that the vast majority of patients
in this patient group had anatomic abnormalities.
Dr Manning. I think that the whole problem is a difficult
chicken-and-egg situation sometimes. Is the valve regurgitation
the problem, or is it the ventricular dysfunction that’s the primary
problem? Perhaps, particularly with some of these patients, what
you’re showing is there is a significant red flag. and you can repair
the valve all you want but the ventricle is still the problem and
that’s failing.
I think this is very useful information, and further long-term
follow-up looking at trying to get these kids out to 20 and 30 years
is really what we’re all striving for.rdiovascular Surgery c Volume 142, Number 2 335
